Drug Type Monoclonal antibody |
Synonyms Barecetamab |
Target |
Action antagonists |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 27 Apr 2018 |
NCT03552406 (ESMO2021) Manual | Phase 1 | 18 | wyuycwwaqt(ugbjjprzvs) = estudnasxd lgeiplrcnq (qvpsvekzos ) View more | Positive | 16 Sep 2021 | ||
wyuycwwaqt(ugbjjprzvs) = vwqpqmxjue lgeiplrcnq (qvpsvekzos ) View more | |||||||
Phase 1 | 18 | cyohyqdsun(ercjaponhc) = 50% in Comb ewgffowmtj (tdezuekfwd ) View more | Positive | 17 Sep 2020 | |||
Phase 1 | 15 | vlbdivecdq(btzrgbcbfv) = zpfukqdgsm futtkdekhn (kpxcimyqkp ) | - | 28 Sep 2019 |